US4490289A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Homogeneous human interleukin 2
Assignee: Hoffmann La Roche Inc
•
Filing: 1982-09-16
•
Granted: 1984-12-25
•
Expires: 2002-09-16
Abstract
Abstract Human interleukin 2 (IL-2) derived from induced human malignant cells has been purified to homogeneity using multiple high performance liquid chromatography (HPLC) steps. The purified IL-2 exhibits potent activity promoting the long-term in vitro culture of antigen-specific effector T-lymphocytes and in modulating lymphocyte reactivity.
Inventors
- 👤 Alvin S. Stern
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:26
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61P; A61P37/00; A61P37/02; A61P37/04; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/827; Y10S530/828; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/141
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
134 words
A process for preparing human interleukin 2 in homogeneous form which process comprises in combination: A. passing a solution of crude human interleukin 2 through a reverse phase high performance column containing methyl or octyl groups covalently bonded to silica gel whereby said human interleukin 2 is retained by said column, eluting said column under HPLC conditions with a buffered n-propanol 0-60% gradient and pooling fractions exhibiting human interleukin 2 activity; and B. passing the pooled active fractions from step A above through a reverse phase high performance column containing diphenyl groups covalently bonded to silica gel whereby said human interleukin 2 is retained by said column, eluting said column under HPLC conditions with a buffered n-propanol 20-60% gradient and pooling fractions exhibiting human interleukin 2 activity and optionally repeating step A and/or B.
Claim 2
Dependent Claim
134 words
A process for preparing human interleukin 2 in homogeneous form which process comprises in combination: A. passing a solution of crude human interleukin 2 through a reverse phase high performance column containing methyl or octyl groups covalently bonded to silica gel whereby said human interleukin 2 is retained by said column, eluting said column under HPLC conditions with a buffered n-propanol 0-60% gradient and pooling fractions exhibiting human interleukin 2 activity; and B. passing the pooled active fractions from step A above through a reverse phase high performance column containing diphenyl groups covalently bonded to silica gel whereby said human interleukin 2 is retained by said column, eluting said column under HPLC conditions with a buffered n-propanol 20-60% gradient and pooling fractions exhibiting human interleukin 2 activity and optionally repeating step A and/or B.
Claim 3
Dependent Claim
15 words
The process of claim 2 wherein said column in step A is an octyl column.
Claim 4
Dependent Claim
34 words
The process of claim 3 wherein said silica gel in said octyl column has a pore size of about 150 Å and in said diphenyl column has a pore size of about 300 Å.
Claim 5
Dependent Claim
20 words
The process of claim 4 wherein said buffer in steps A and B is 0.9M acetic acid/0.2M pyridine, pH 4.0.
Claim 6
Dependent Claim
19 words
The process of claim 2 wherein said crude human interleukin 2 is derived from induced, cultured human malignant cells.
References Cited (Backward Citations)
US4390623A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-12-25 | 1988-06-25 | 1988-12-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-12-25 | 1992-06-25 | 1992-12-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-12-25 | 1996-06-25 | 1996-12-25 | $7700.00 | Window Closed / Lapsed |